Please wait while the formulary information is being retrieved.
Drug overview for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
Generic name: s-adenosylmeth/collagen/hyaluronic/Boswellia/turmeric/pepper
Drug class:
Therapeutic class: Alternative Therapy
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: s-adenosylmeth/collagen/hyaluronic/Boswellia/turmeric/pepper
Drug class:
Therapeutic class: Alternative Therapy
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| S-Adenosylmethionine (SAM-e)/Tranylcypromine SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: S-adenosylmethionine (SAMe), and tranylcypromine are suggested to have similar effects on the serotonin pathway, therefore their use together may result in additive or synergistic effects. CLINICAL EFFECTS: Concomitant use of S-adenosylmethionine and antidepressants which inhibit neuronal serotonin reuptake may result in serotonin syndrome. Symptoms of serotonin syndrome may include tremor, agitation, diaphoresis, hyperreflexia, clonus, tachycardia, hyperthermia, and muscle rigidity.(2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of tranylcypromine states that concurrent use of S-adenosylmethionine and tranylcypromine is contraindicated.(1) If concurrent therapy is warranted, patients should be monitored for signs and symptoms of serotonin syndrome. Instruct patients to report muscle twitching, tremors, shivering and stiffness, fever, heavy sweating, heart palpitations, restlessness, confusion, agitation, trouble with coordination, or severe diarrhea. DISCUSSION: There is a case report with a tricyclic antidepressant (clomipramine) and tranylcypromine of serotonin syndrome. Tricyclic antidepressants are also known to increase serotonin levels.(2) |
PARNATE, TRANYLCYPROMINE SULFATE |
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Selected Chemotherapy Agents/Turmeric (Curcumin) SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Curcumin, the major component of turmeric, has been shown to decrease chemotherapy-induced apoptosis by inhibition of reactive oxygen species generation and blockade of the c-Jun NH2-terminal kinase pathway.(1) CLINICAL EFFECTS: Concurrent use of turmeric (curcumin) may decrease the effectiveness of some chemotherapy agents.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients receiving cytotoxic therapy for breast cancer should be excluded from curcumin-based chemotherapy.(1) It would be prudent to instruct patients to avoid or limit consumption of curcumin or turmeric. DISCUSSION: In vitro studies in MCF-7 cancer cell lines showed that curcumin decreased camptothecin-induced, doxorubicin-induced, and mechlorethamine-induced apoptosis. In vivo tests in mice xenograft models of human breast cancer, dietary curcumin decreased cyclophosphamide-induced tumor regression.(1) |
ADRIAMYCIN, CAELYX, CAMPTOSAR, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, DOXIL, DOXORUBICIN HCL, DOXORUBICIN HCL LIPOSOME, FRINDOVYX, HYCAMTIN, IRINOTECAN HCL, MECHLORETHAMINE HCL, ONIVYDE, TOPOTECAN HCL |
| Cladribine/Selected Inhibitors of BCRP SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inhibitors of BCRP may increase the absorption of cladribine.(1-2) CLINICAL EFFECTS: The concurrent administration of cladribine with an inhibitor of BCRP may result in elevated levels of cladribine and signs of toxicity.(1-2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of cladribine states concurrent use of BCRP inhibitors should be avoided during the 4- to 5-day cladribine treatment.(1-2) Selection of an alternative concurrent medication with no or minimal transporter inhibiting proprieties should be considered. If this is not possible, dose reduction to the minimum mandatory dose of the BCRP inhibitor, separation in timing of administration, and careful patient monitoring is recommended.(1-2) Monitor for signs of hematologic toxicity. Lymphocyte counts should be monitored. DISCUSSION: Cladribine is a substrate of BCRP. Inhibitors of this transporter are expected to increase cladribine levels.(1-2) BCRP inhibitors linked to this monograph include: capmatinib, clopidogrel, cobicistat, curcumin, danicopan, darolutamide, eltrombopag, elvitegravir, grazoprevir, lazertinib, oteseconazole, pacritinib, ritonavir, roxadustat, tafamidis, ticagrelor, turmeric, and vadadustat.(1-4) |
CLADRIBINE, MAVENCLAD |
There are 0 moderate interactions.
The following contraindication information is available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Biliary calculus |
| Gallbladder disease |
There are 0 severe contraindications.
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Disease of liver |
| Gastroesophageal reflux disease |
The following adverse reaction information is available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Drug-induced hepatitis |
There are 13 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Abdominal distension Abdominal pain with cramps Constipation Diarrhea Dyspepsia Flatulence Gastritis Gastroesophageal reflux disease Nausea Pruritus of skin Tongue discoloration Urticaria Vomiting |
The following precautions are available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for EB-A7 DR (s-adenosylmeth/collagen/hyaluronic/boswellia/turmeric/pepper)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool